By Sabela Ojea
Shares of Sanuwave Health climbed on the path toward their highest close in almost three years after the company guided for further growth in 2025.
The stock gained 13%, to $36.20, in Friday afternoon trading. Shares are up 57% year to date.
The developer of patented noninvasive, biological response activating devices said it expects revenue of $48 million to $50 million for 2025 as it guided for a first-quarter top-line performance between $8.4 million and $9 million.
In 2024, the company had reported revenue of $32.6 million.
"We are confident that our revenue pipeline is stronger than it has ever been and have been ramping up our sales force and sales strategy to meet this opportunity and to effectively manage the larger customers with whom we continue to engage," Chief Executive Morgan Frank said.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
March 21, 2025 15:05 ET (19:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.